| Literature DB >> 33907481 |
Hye-In Choi1, Hae-Jin Ko2, Ji-Eun Song3, Ji-Yeon Park3, Jin-Hee Kim3.
Abstract
PURPOSE: To evaluate the results of operating an in-hospital coronavirus disease 2019 screening station on an outpatient basis and to identify the effectiveness and necessity of such a screening station. PATIENTS AND METHODS: This cross-sectional study included 1345 individuals who were tested for COVID-19 using real-time reverse transcription polymerase chain reaction (RT-PCR) at an in-hospital screening station on an outpatient basis. The subjects were healthcare workers (HCWs) with suspected COVID-19 symptoms or exposure to patients with confirmed COVID-19, caregivers at the hospital for complete enumeration, and patients who were scheduled to be admitted to a nonrestricted area in the hospital or to visit for outpatient treatment, but had suspected COVID-19 symptoms. The subjects were divided and compared as follows: HCW versus non-HCW groups and RT-PCR positive versus negative groups.Entities:
Keywords: coronavirus disease 2019; healthcare workers; hospital infection; nocebo effect; screening
Year: 2021 PMID: 33907481 PMCID: PMC8064719 DOI: 10.2147/RMHP.S287213
Source DB: PubMed Journal: Risk Manag Healthc Policy ISSN: 1179-1594
Figure 1Illustration of in-hospital COVID-19 screening station.
Baseline Characteristics of Total Study Population and the Two Groups of Subjects Divided by HCW and Non-HCW (Occupational Status)
| Total (n = 1345) | HCWs (n = 624, 47.4%) | Non-HCWs (n = 721, 52.6%) | ||
|---|---|---|---|---|
| Age, y | 46.40 ± 8.33 | 34.90 ± 10.51 | 56.36 ± 17.82 | 0.000 |
| Sex | 0.000 | |||
| Male | 423 (31.4%) | 153 (24.5%) | 270 (37.4%) | |
| Female | 922 (68.6%) | 471 (75.5%) | 451 (62.6%) | |
| Exposure | 227 (16.9%) | 208 (33.3%) | 19 (2.6%) | 0.000 |
| Purpose of examination | 0.000 | |||
| Exhibiting symptoms | 410 (30.5%) | 371 (59.5%) | 39 (5.4%) | |
| Wanted | 291 (21.6%) | 241 (38.6%) | 50 (6.9%) | |
| Screening | 664 (47.9%) | 12 (1.9%) | 632 (87.7%) | |
| COVID-19 PCR (+) | 7 (0.5%) | 4 (0.6%) | 3 (0.3%) | 0.711* |
| Symptoms related to COVID-19 | 454 (33.8%) | 389 (62.3%) | 65 (9.0%) | <0.001 |
| Fever | 54 (4.0%) | 43 (6.9%) | 11 (1.5%) | <0.001 |
| Sore throat | 266 (19.8%) | 245 (39.3%) | 21 (2.9%) | <0.001 |
| Cough | 221 (16.4%) | 202 (32.4%) | 19 (2.6%) | <0.001 |
| Sputum | 140 (10.4%) | 119 (19.1%) | 21 (2.9%) | <0.001 |
| Muscle pain | 51 (3.8%) | 48 (7.7%) | 3 (0.4%) | <0.001 |
| Rhinorrhea | 40 (3.0%) | 35 (5.6%) | 5 (0.7%) | <0.001 |
| Headache | 22 (1.6%) | 20 (3.2%) | 2 (0.3%) | <0.001 |
| Diarrhea | 19 (1.4%) | 17 (2.7%) | 2 (0.3%) | <0.001 |
| Others | 115 (8.6%) | 99 (15.9%) | 15 (2.1%) | <0.001 |
| Underlying diseases | 355 (26.4%) | 40 (6.4%) | 315 (43.7%) | <0.001 |
| Hypertension | 175 (13.0%) | 18 (2.9%) | 157 (21.8%) | <0.001 |
| Diabetes mellitus | 105 (7.8%) | 4 (0.6%) | 101 (13.9%) | <0.001* |
| Dyslipidemia | 77 (5.7%) | 11 (1.8%) | 66 (9.2%) | <0.001 |
| Cardiovascular disease | 51 (3.8%) | 6 (1.0%) | 45 (6.2%) | <0.001 |
| Hepatobiliary disease | 23 (1.7%) | 3 (0.5%) | 20 (2.8%) | 0.001 |
| Cerebrovascular disease | 16 (1.2%) | 1 (0.2%) | 15 (2.1%) | 0.001 |
| Renal disease | 34 (2.5%) | 1 (0.2%) | 33 (4.6%) | <0.001 |
| Cancer | 96 (7.1%) | 6 (1.0%) | 90 (12.5%) | <0.001 |
| Thyroid disease | 21 (1.6%) | 4 (0.6%) | 17 (2.4%) | 0.011 |
| Respiratory disease | 17 (1.3%) | 0 (0.0%) | 17 (2.4%) | <0.001 |
Notes: Data are presented as mean ± standard deviation or number (%). *Fisher’s exact test.
Figure 2Number of HCWs and non-HCWs by date of visit.
Baseline Characteristics of the Two Groups Divided by RT-PCR Result
| COVID-19 (+) (n = 7) | COVID-19 (−) (n = 1338) | P value* | |
|---|---|---|---|
| Age, y | 45.86 ± 19.15 | 46.40 ± 18.34 | 0.439† |
| Sex | 1.000 | ||
| Male | 2 (28.6%) | 421 (31.55%) | |
| Female | 5 (71.4%) | 917 (68.5%) | |
| HCWs | 4 (57.1%) | 620 (46.3%) | 0.711 |
| Exposure | 5 (71.4%) | 222 (16.6%) | 0.002 |
| Purpose of examination | 0.005 | ||
| Exhibiting symptoms | 3 (42.9%) | 407 (30.4%) | |
| Wanted | 4 (57.1%) | 287 (21.4%) | |
| Screening | 0 (0.0%) | 644 (48.15%) | |
| Symptoms related to COVID-19 | 4 (57.1%) | 450 (33.6%) | 0.235 |
| Fever | 2 (28.6%) | 52 (3.9%) | 0.029 |
| Sore throat | 1 (57.1%) | 262 (19.6%) | 0.032 |
| Cough | 3 (42.9%) | 218 (16.3%) | 0.092 |
| Sputum | 0 (0.0%) | 140 (10.5%) | 1.000 |
| Muscle pain | 0 (0.0%) | 51 (3.8%) | 1.000 |
| Rhinorrhea | 1(14.3%) | 39 (2.9%) | 0.191 |
| Headache | 0 (0.0%) | 22 (1.6%) | 1.000 |
| Diarrhea | 0 (0.0%) | 19 (1.4%) | 1.000 |
| Others | 0 (0.0%) | 114 (8.5%) | 1.000 |
| Underlying diseases | 0 (0.0%) | 355 (26.5%) | 0.200 |
| Hypertension | 0 (0.0%) | 175 (13.1%) | 0.604 |
| Diabetes mellitus | 0 (0.0%) | 105 (7.9%) | 1.000 |
| Dyslipidemia | 0 (0.0%) | 77 (5.8%) | 1.000 |
| Cardiovascular diseases | 0 (0.0%) | 51 (3.8%) | 1.000 |
| Hepatobiliary disease | 0 (0.0%) | 23 (1.7%) | 1.000 |
| Cerebrovascular disease | 0 (0.0%) | 16 (1.2%) | 1.000 |
| Renal disease | 0 (0.0%) | 34 (2.5%) | 1.000 |
| Cancer | 0 (0.0%) | 76 (7.2%) | 1.000 |
| Thyroid disease | 0 (0.0%) | 21 (1.6%) | 1.000 |
| Respiratory disease | 0 (0.0%) | 17 (1.3%) | 1.000 |
Notes: *Fisher’s exact test. †Mann–Whitney U-test.
Clinical Characteristics of Patients with Confirmed COVID-19
| No. | Sex/Age | Status | Exposure | Symptom | Date of Examination | Underlying Diseases | |
|---|---|---|---|---|---|---|---|
| Date of Onset | |||||||
| 1 | F/24 | Nurse | – | 02.21 | F, ST, C, R | 02.21 | – |
| 2 | F/33 | Nurse | – | 02.29 | ST, C | 03.02 | – |
| 3 | F/23 | Nurse | + | 03.01 | ST, C | 03.02 | – |
| 4 | M/49 | Others | + | 03.02 | ST, C | 03.03 | |
| 5 | F/61 | Caregiver | + | – | – | 03.03 | – |
| 6 | M/69 | Caregiver | + | – | – | 03.03 | – |
| 7 | F/62 | Caregiver | + | – | – | 03.03 | – |
Abbreviations: C, cough; F, fever; R, rhinorrhea; ST, sore throat.
Logistic Regression Analysis Using Enter Method for COVID-19 Suspected Symptoms and Characteristics of Subjects
| Independent Variables | Odds Ratio | 95% Confidence Interval | |
|---|---|---|---|
| Employment status | |||
| Non-employees | 1.000 | ||
| Employees | 23.317 | 15.142–35.907 | <0.001 |
| Age | 1.003 | 0.992–1.015 | 0.568 |
| Sex | |||
| Male | 1.000 | ||
| Female | 1.027 | 0.75–1.404 | 0.866 |
| Exposed to confirmed COVID-19 patients | |||
| No | 1.000 | ||
| Yes | 0.719 | 0.512–1.010 | 0.057 |
| Underlying disease | |||
| No | 1.000 | ||
| Yes | 1.453 | 0.933–2.262 | 0.099 |